$32,940.30 consulting Payment -- AbbVie Inc to Dr. Jeffrey Campbell

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report details a payment of $32,940.3 from AbbVie Inc. to Dr. Jeffrey Campbell, an oncologist in Pittsburgh, PA, on March 8, 2025. The payment was for consulting services related to Wegovy. Consulting fees are a common way pharmaceutical companies engage with physicians. These arrangements can involve advising on drug development, marketing strategies, or providing expert opinions on clinical practice. The amount, while substantial, is not necessarily out of the ordinary for specialized consulting work in a field like oncology, especially if it involves significant time commitment or expertise. However, it is higher than the average payment received by many physicians. Potential conflicts of interest are a key consideration. When a physician receives significant payments from a drug manufacturer, there's a theoretical risk that their prescribing decisions could be influenced, consciously or unconsciously, by these financial ties. This doesn't mean Dr. Campbell's judgment is compromised, but it's a factor patients should be aware of. The Sunshine Act aims to increase transparency around these relationships, allowing patients to be informed. Compared to industry averages, this payment is on the higher end. While many oncologists receive payments, the total amount and the nature of consulting can vary widely. AbbVie is a major pharmaceutical company, and Wegovy is a significant drug, suggesting a potentially high level of engagement. For patients, understanding these relationships is crucial. It means being an informed consumer of healthcare. While Dr. Campbell's expertise is valuable, patients should feel empowered to discuss any concerns about his relationships with pharmaceutical companies and ensure their treatment decisions are based on their individual medical needs and the best available evidence, not solely on the doctor's financial ties. Transparency through the Open Payments database is a tool to facilitate this informed dialogue.

Patient Guidance: What This Payment Means for You

It's understandable to feel curious or even concerned when you see a payment like this. The good news is that the Sunshine Act makes this information public, so you can be informed. This payment was for consulting, meaning Dr. Campbell likely provided expert advice to AbbVie. While this amount is significant, it doesn't automatically mean your care will be affected. However, it's always wise to maintain an open dialogue with your doctor. At your next appointment, you can ask, 'I saw that you received a payment from AbbVie for consulting. Can you tell me more about that relationship and how it might relate to the treatments you recommend?' This is a direct but respectful way to open the conversation. Remember, most doctors value transparency and want you to feel comfortable. If you have specific concerns about a medication or treatment plan, discuss them openly. Payments for consulting or speaking are common in many specialties, but if you feel a doctor is pushing a specific drug without clear medical justification, or if their financial ties seem extensive and undisclosed, that's when it warrants closer attention.

Payment Context: Is This Amount Normal?

Payments to oncologists for consulting can be quite common and vary significantly in amount. Oncology is a field with complex treatments and significant drug development, leading to frequent industry engagement. While many oncologists may receive payments, the total amount and frequency can differ greatly, with some receiving nominal amounts and others substantial sums for specialized advisory roles.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, requires pharmaceutical and medical device companies to report payments and other transfers of value made to physicians and teaching hospitals. Consulting fees fall under these reporting requirements. Payments exceeding a certain threshold (which can vary annually but is generally low for direct payments) must be disclosed. This type of payment is subject to standard reporting and transparency requirements, aiming to shed light on industry-physician financial relationships.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• oncology
• consulting-fees
• sunshine-act
• conflict-of-interest
• abbvie
• wegovy

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can find out by searching the CMS Open Payments database online. This database lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. Simply enter your doctor's name or NPI number. Seeing payments doesn't automatically mean there's a problem; it's about transparency. Many physicians engage with industry for legitimate reasons, like providing expert feedback or participating in research. The key is understanding the nature and amount of these payments to assess potential influences on care.

Should I worry about this payment?

This specific payment of $32,940.3 from AbbVie to Dr. Campbell for consulting is a substantial amount, placing it on the higher end of typical payments. While consulting is a legitimate activity, such a significant sum warrants awareness. It doesn't automatically mean your care is compromised, but it highlights a strong financial relationship. Consider it a prompt to ensure your treatment decisions align with your needs and evidence-based medicine. If you have concerns, discuss them openly with Dr. Campbell or seek a second opinion.

What types of pharma payments are most concerning?

Payments that raise the most concern are often those that directly incentivize prescribing or influence clinical judgment without clear educational or research value. This includes large speaker fees for promoting specific drugs, consulting fees for advisory boards that seem to rubber-stamp company agendas, or significant 'research' payments where the research is minimal or biased. Payments for genuine research, speaking at accredited educational events, or providing expert input on drug development are generally viewed as less concerning, but transparency is always key.

How do I talk to my doctor about pharma relationships?

Start by stating what you've observed factually and express your desire for clarity. You could say, 'I noticed on the Open Payments website that you've received payments from [Company Name]. Could you help me understand what that relationship entails and how it might inform the treatments you recommend for me?' Be specific about your concerns. Ask questions like, 'Are there alternative treatments available that aren't from this company?' or 'How do you ensure your prescribing decisions are based solely on my medical needs?' A good doctor will welcome these questions.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these payments are accurately reported under the Sunshine Act. The Act's purpose is not to prohibit these relationships but to make them transparent. Payments must be disclosed if they meet certain thresholds. Doctors can be compensated for legitimate activities like consulting, speaking at educational events, research, or providing expert advice. The legality hinges on proper disclosure and ensuring the payments are for bona fide services, not inducements.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships between doctors and pharmaceutical companies can influence prescribing patterns. Doctors who receive payments may be more likely to prescribe the company's drugs, sometimes even when equally effective or cheaper alternatives exist. This influence can be subtle and unconscious. While many physicians strive for objectivity, awareness of these potential biases is important for patients. Openly discussing treatment options and alternatives with your doctor is the best way to ensure your care is patient-centered.

How does this compare to other doctors in this specialty?

Oncology is a specialty where industry engagement is common due to the high cost and complexity of cancer treatments. While many oncologists receive payments, the amount of $32,940.3 for consulting is on the higher side compared to the average payment received by physicians across all specialties. It suggests a more significant level of engagement with AbbVie than a one-off interaction. However, without knowing the specifics of the consulting work, it's hard to definitively label it as 'high' or 'low' within the oncology field itself, as consulting roles can be very demanding.

What is Wegovy?

Wegovy (semaglutide) is a prescription medication used for chronic weight management in adults with obesity or who are overweight and have at least one weight-related condition. It belongs to a class of drugs called GLP-1 receptor agonists. Wegovy works by mimicking a hormone that helps regulate appetite, making you feel fuller and reducing hunger. It is typically administered as a weekly injection. AbbVie Inc. is a pharmaceutical company, but Wegovy is actually manufactured by Novo Nordisk. This payment from AbbVie might be related to their research or development in a related therapeutic area, or potentially a misunderstanding in the provided data linking AbbVie to Wegovy directly in this context.

Related Reports

• View Dr. Jeffrey Campbell's full payment report
• AbbVie Inc full spending report
• Browse all Oncology payments
• Browse all payments in Pennsylvania
• Search for other payments